In a small study, 34% of dialysis patients had vertebral fractures, and patients in the highest tertile of parathyroid hormone level had a nearly 3-fold increased risk of these fractures compared with those in the middle tertile.
New data support aggressive vitamin D repletion to a revised serum 25-hydroxyvitamin D target of at least 51 ng/mL in patients with chronic kidney disease.
Twice as many patients taking a high cinacalcet dose before transplantation required subsequent parathyroidectomy persistent secondary hyperparathyroidism.
A European study of hemodialysis patients who were new users of cinacalcet found that the drug was discontinued in 35% of patients after 1 year.
Dialysis patients who underwent parathyroidectomy had a 24% greater risk for cardio- and cerebrovascular events than similar patients who did not undergo the surgery.
In a study, hypocalcemia and gastrointestinal adverse events were managed through etelcalcetide dose modification or discontinuation.
In a large study of dialysis patients, serum 25-hydroxyvitamin D levels peaked in summer and declined in winter.
In 2 small trials of Japanese patients with SHPT on dialysis, evocalcet treatment reduced iPTH to target levels in a majority of patients within 30 to 32 weeks.
At 6 months after surgery, just 6.7% TPTx + AT had parathyroid hormone levels exceeding 200 pg/mL, compared with 38.9% of SPTx patients
In a small study, vitamin K antagonist use and liver dysfunction emerged as the most important factors in the development of calciphylaxis.
